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Abstract
Background: Maspin, a non-inhibitory member of the serine protease inhibitor superfamily, has been characterized
as a tumor suppressor gene in multiple cancer types. Chemotherapeutic insensitivity is one of major obstacles to
effectively treating muscle invasive bladder cancer (MIBC). This study was conducted to investigate the role and
probable mechanism of Maspin enhancing cisplatin chemosensitivity of bladder cancer in vitro and MIBC patients.
Methods: Maspin expression was quantified by qRT-PCR in two MIBC cell lines (T24 and 5637). After successful
established Maspin overexpression model by lipidosome transfection, MTT and cell apoptosis assay were used to
assess the MIBC’s cisplatin sensitivity. Western blot method was used to test PI3K/ AKT/mTOR signal passway and
apoptosis related molecules Caspase3 and Bcl-2. Additionally, we evaluated Maspin expression and prognosis in 62
MIBC cases who underwent cisplatin based neoadjuvant chemotherapy (NACT) using immunohistochemistry.
Result: Upregulate Maspin expression could enhance the chemosensitivity induced by cisplatin in T24 and 5637
cell lines. The cell viability, cloning ability and IC50 were reduced while apoptosis rate was upregulated when cells
were transfected Maspin. Phospho(p)-AKT, PI3K, mTOR, and Bcl-2 expression were significantly decreased, whereas
Caspase3 was greatly increased in the Maspin group. In the clinic study, there was significant correlation between
Maspin expression and overall survival (OS) and progression-free survival (PFS) rate in MIBC patients who received
cisplatin based NACT.
Conclusion: Maspin could enhance cisplatin chemosensitivity in T24 and 5637 cell lines. Its expression correlated
with prognosis of MIBC patients who received cisplatin based neoadjuvant chemotherapy.
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Background
Bladder cancer is one of the most common types of
urinary tract malignancy, with an estimated 429,800 new
cases of bladder cancer and 165,100 deaths occurred in
2012 worldwide. Incidence rates are highest in Europe,
Northern America, Western Asia, and Northern Africa
[1]. It is clinically characterized by its progression, recur-
rence, metastasis, and drug resistance [2]. At initial diag-
nosis, approximately 70 % of cases are diagnosed as
non-muscle invasive bladder cancer (NMIBC) and ap-
proximately 30 % as muscle-invasive bladder cancer
(MIBC) [3]. Although the majority of patients presenting
with superficial disease have a favorable prognosis, ap-
proximately 70 % of these develop disease recurrence
and 10 to 20 % of these patients progress to MIBC [4, 5].
The standard treatment for MIBC is radical cystectomy,
which only provides a mere five-year survival rate of 50 %
[6]. In order to improve the effects of treatment, peri-
operative chemotherapy has been explored since the
1980s. Although cisplatin is the first-line chemotherapy
for advanced bladder cancer, the cisplatin/gemcitabine
(GC) regimen has a median time-to-progression of only
six months and has no effect on overall survival after
radical cystectomy in high-risk patients [7]. Cancer cell
resistance to cisplatin is a major obstacle to the effective
treatment of bladder cancer, and the underlying mecha-
nisms of the resistance are unclear till now.
Maspin (mammary serine protease inhibitor), is a mem-
ber of the serine protease inhibitor/non-inhibitor super-
family. Recent studies showed it was a tumor suppressor
gene in multiple cancers. Its effects included inhibition of
cancer cell invasion, attachment to extracellular matrices,
increased sensitivity to apoptosis, and inhibition of angio-
genesis [8, 9]. Maspin expression was found in high quan-
tities in normal urothelium. It was preserved in superficial
bladder cancer but significantly diminished in invasive
carcinoma. And within the group of invasive cancers, it
was found that maspin expression was associated with
good prognosis [10]. There were some reports of Maspin
enhancing chemosensitivity in ovarian and breast car-
cinoma cells [11, 12]. Also, clinic relevance of Maspin
expression and adjuvant chemotherapy prognosis in
advanced gastric cancer was confirmed [13]. But its role
and mechanism in chemosensitivity of bladder cancer
remain unclear. So, in the current study, we investigated
the role and probable mechanism of Maspin enhancing




The MIBC cell lines T24, 5637 and human bladder epi-
thelial cell line SV-HUC-1 were obtained from American
Type Culture Collection (ATCC). Cells were cultured in
1640 medium (Invitrogen, Carlsbad, CA) with 10 % FBS
(Invitrogen) and 1 % penicillin/streptomycin (Invitrogen).
All cells were cultured in a sterile incubator maintained
with 5 % CO2 at 37 °C.
Real-time RT-PCR
Total RNA was extracted from cells with Trizol reagent
(Invitrogen) according to the manufacturer’s instruc-
tions. The relative expression level of Maspin was deter-
mined by quantitative real-time RT-PCR using standard
SYBR Green RT-PCR Kit (Takara, Otsu, Japan). The spe-
cific primer pairs are as follows: Maspin sense, 5′-CT
GACAACAGTGTGAACGAC-3′, antisense, 5′-CAAGC
CTTGGGATCAATC ATCT-3′; β-actin as an internal
control, sense, 5′-AGGGGCCGGACTCGTCATAC T-3′
and antisense, 5′-GGCGGCACCAC CATGTACCCT-3′.
The relative expression of Maspin mRNA was quantified
using the GraphPad Prism 4.0 software (GraphPad Soft-
ware, San Diego, CA, USA) and 2-ΔΔCt method.
Western blot analysis
Protein levels were quantified by Bradford assay. The
protein sample was diluted, heated for denaturation, and
then subjected to dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred onto poly-
vinylidene fluoride membranes (PVDF, Millipore). The
membrane was blocked in 0.1 % Triton X-100 and 5 %
non-fat milk powder in phosphate-buffered saline for
1 h at 4 °C and then probed with β-actin (1:2000, Santa
Cruz Biotechnology, Santa Cruz, CA) rabbit polyclonal
primary antibody. After washing 3 times with Tris-
buffered saline Tween (TBST), the membrane was incu-
bated in peroxidase-conjugated goat anti-rabbit IgG
antibody (1:4000, Immunoway, USA). Bands were visu-
alized by an enhanced chemiluminescence detection
system using medical X-ray films and quantified by IPP6.0
analysis software. The intensities of band of interest were
expressed relative to the β-actin intensities from the
same sample.
Transfection
Cells were trypsin-digested and seeded onto six-well plates
the day prior to the transfection to ensure 60–70 % cell
confluence on the day of transfection. pcDNA3.1-Maspin
recombinant plasmids were constructed (Data not shown)
and transfected into T24 and 5637 cell lines using Lipofec-
tamine 2000 (Invitrogen) according to the manufacturer’s
recommendations. pcDNA3.1 without Maspin plasmids
were also transfected into these two cell lines as negtive
control (NC) groups.
Cell proliferation assay
Cells in exponential growth were plated at a concentration
of 3 × 103 cells/well in 96-well plates for 24 h before use.
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The culture medium was replaced with fresh medium
containing cisplatin with different concentrations for 72 h.
Next, MTT (20 μl/well) was added to each well. After 2 h
further incubation, the optical density at 570 nm (OD570)
of each well was measured with an ELISA reader (ELX-
800, Bio-Tek). The inhibition rate for every concentration
and the IC50 (the concentration of drug that results
in 50 % of the control value) were calculated using
Graphpad5 software.
Cell apoptosis assay
Forty-eight hours after transfection, all group cells were
seeded at a density of 5x105 cells per 10-mm dish, and
treated with cisplatin at proper concentration for 24 h,
respectively. Then the cells were collected by brief tryp-
sinization and washed twice in PBS. After incubation
with 5 μl of Annexin V-FITC and 10 μl of propidium
iodide (PI) at room temperature for 15 min in dark, cells
were analyzed by flow cytometry (BD, NJ, USA). Apop-
tosis cells were recognized as high Annexin V fluorescence
signal with low PI signal. The percentages of apoptotic
cells were calculated by data from FACS analysis.
Colony-formation assay
For all groups, 3 ml complete medium containing 150
cells were added to each well of a six-well plate. Plates
were incubated at 37 °C, 5 % CO2 for 14 days. After
that, cells were gently washed and stained with Giemsa.
Colonies containing at least 50 cells were counted.
Patients and tumor samples
From January 2010 to January 2014, 62 MIBC patients
who received cisplatin based neoadjuvant chemotherapy
(NACT) and laparoscopic radical cystectomy and pelvic
lymph node dissection (RC-PLND) in our center were
included in this study. We obtained ethics approval from
the ethics committee at Xiangya Hospital, Central South
University. Written informed consent was obtained from
all participants in our study. Table 1 showed details of
patients and tumor characteristics. Follow-up informa-
tion was available for all 62 patients with a follow-up
time of 36.1 (range from 16 to 64) months. Tumor sta-
ging was determined by 2009 UICC-TNM staging sys-
tem and tumor grading was according to 1973 WHO
grading system. The chemotherapy of GC regimen were
as follows: gemcitabine 1000 mg/m2, 1d-1, 8d −1; cis-
platin 70 mg/m2, 2d −1. a 21-day cycle for 3–4 cycles.
NACT was administered GC regimen within 16 weeks
before surgery.
Tissue immunohistochemistry
Immunohistochemical (IHC) staining for Mapsin protein
was carried out using an SP ready-to-use kit (Zhongshan
Jinqiao Biotechnology, Zhongshan, China) according to the
manufacturer’s recommendation. Briefly, deparaffinization
and rehydration were done before paraffin-embedded sec-
tions (4 μm thick) were immersed in 0.01 Mcitric buffer
(pH 6.0). The slides were then incubated with 3 % hydro-
gen peroxide for 10 min, followed by incubation in normal
goat serum for 10 min at room temperature. Maspin
antibody (monoclonal mouse antibody; NCL-Maspin,
Novocastra Laboratories Ltd.) was used at a dilution of
1: 200 as the first antibody according to the manufac-
turer’s instructions. Sections were then incubated with
goat anti-polyvalent antibody for 10 min and subsequently
with streptavidin peroxidase for 10 min. The slides were
visualized using diaminobenzidine and counterstained
with hematoxylin before microscopy.
The IHC score was assessed independently by two sur-
gical pathologists. The number of immunoreactive cells
was quantified as ‘proportion score’, including 0; no im-
munoreactive cells, 1; the numbers of immunoreactive
cells were less than 1 %, 2; less than 10 %, 3; less than
one-thirds, 4; less than two-thirds, 5; more than two-
thirds. The highest number of immunoreactive tumor
cells was graded as ‘intensity score’, including 0; no im-
munoreactivity, 1; weak staining intensity, 2; intermedi-
ate, 3; strong. The IHC results were grouped based on
the IHC score (proportion score plus intensity score):
0–2, negative(−); 3–8, positive(+). In case of disagree-
ment, the score was reevaluated and consensus was
reached [14].
Statistical analysis
Results were expressed as the means ± standard deviation
(SD) from at least three separate experiments. Statistical
Table 1 Patient Characteristics
Total patients (n) 62
Age (year) 60.5 (39–78)
Gender (n, %)
Male 43 (69.4 %)
Female 19 (30.6 %)
Grade (n, %)
Grade 1 4 (6.5 %)
Grade 2 30 (48.4 %)
Grade 3 28 (45.1 %)
TNM stage (n, %)
pT2N0 14 (22.6 %)
pT2N+ 5 (8.1 %)
pT3N0 11 (17.7 %)
pT3N+ 16 (25.8 %)
pT4aN0 3 (4.8 %)
pT4aN+ 13 (21.0 %)
Follow-up time (months) 36.1 (16–64)
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analysis was carried out using SPSS 16.0 software. Student’s
t-test was used to compare the relative amounts of mRNAs
and proteins. Survival curves were plotted by the Kaplan–
Meier method, and differences were examined by the log-
rank test. A value of P < 0.05 was considered to indicate
statistical significance.
Results
Different expression of Maspin in bladder cancer and
normal bladder epithelial cell lines
To delineate the potential role of Maspin in bladder can-
cer, we compared the protein level in bladder normal
and cancer cells. The protein levels of Maspin in MIBC
cell lines were determined using western blot. Down-
regulation of Maspin was observed in bladder cancer cell
lines. The densitometry evaluation of the western blots
showed that Maspin expression was significantly decreased
in bladder cancer T24 and 5637 cell lines as compared
the control group SV-HUC-1, respectively. (P < 0.05)
(Fig. 1a, b). These results suggest that Maspin may play
an important role in malignant progression of bladder
cancer.
Expression levels of Maspin post-transfection in bladder
cancer T24 and 5637 cells
To clarify the functions of Maspin in bladder cancer
T24 and 5637 cells, gain-of-function cell models were
constructed by transfecting with pcDNA3.1-Maspin.
Compared with blank control group (Con) and negative
control group (NC), Maspin mRNA (Fig. 2a, b) and pro-
tein (Fig. 2c, d) level was significantly up-regulated when
transfected with pcDNA3.1-Maspin in T24 and 5637
cells (P < 0.05).
Maspin inhibits proliferation and enhancing the
sensitivity to cisplatin of bladder cancer T24 and
5637 cells
To investigate the effects of Maspin on proliferation and
sensitivity to cisplatin of bladder cancer T24 and 5637
cells, we used MTT and colony formation assay. The
results showed both cells viability were reduced with the
increasing of cisplatin concentrations. Overexpression of
Maspin dramatically decreased the survival rate (Fig. 3a)
of both T24 and 5637 cells as compared with that of
Con and NC group (P < 0.05). The IC50 results showed
that Maspin overexpression increased the sensitivity of
both T24 and 5637 cells to cisplatin, with the IC50 value
decreasing from 23.32 ± 4.30 mg/l to 15.30 ± 2.10 mg/l
and from 4.91 ± 0.42 mg/l to 2.14 ± 0.21 mg/l, respectively
(Fig. 3b). Also, clone-formation assay showed the cells
proliferation were inhibited in Maspin group of T24 and
5637 (P < 0.05) (Fig. 3c, d). It suggested that Maspin could
inhibit the proliferation and enhance sensitivity to cis-
platin of T24 and 5637 cells.
Maspin increase cell apoptosis induced by cisplatin in T24
and 5637 cells
To determine whether the Maspin-induced growth in-
hibition was mediated by apoptosis, we further used the
flow cytometry to identify the cell apoptosis rate. We
evaluate the influence of Maspin on T24 and 5637 cells
apoptosis induced by 25 mg/L and 6 mg/L cisplatin. As
showed in Fig. 4, the apoptosis rates were elevated in all
group (Con, NC and Maspin) when adding the cisplatin.
Overexpression of Maspin increase T24 and 5637 cells
apoptosis at about 12.48 and 12.53 % (from 15.60–28.08 %
and from 19.70–32.23 %), respectively. (P < 0.05). This was
consistent with the change of drug sensitivity and demon-
strated that Maspin induced chemosensitivity alteration was
probably mediated by the cell apoptosis pathway.
The probable mechanism of upregulation of Maspin
enhances cisplatin-induced chemosensitivity in T24 and
5637 cells
To further elucidate the probable mechanism of Maspin
enhancing cisplatin-induced chemosensitivity in T24 and
5637 cells, western blotting analysis was used to examine
the effects on AKT, phospho(p)-AKT, PI3K, mTOR,
Caspase3 and Bcl-2 protein expressions. All groups
were conducted after cells culture in IC50 cisplatin
Fig. 1 The protein level of Maspin in bladder cancer T24, 5637 and normal bladder epithelial SV-HUC-1 cell lines. Data were shown in the grayscale (a)
and bar chart (b), respectively. Maspin expression was significantly decreased in bladder cancer T24 and 5637 cell lines as compared the control group
SV-HUC-1. *P < 0.05. Three independent experiments were performed (n = 3)
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enviroment. Our results showed that PI3K, which could
activate AKT, was downregulated after Maspin overexpres-
sion (P < 0.05). Though AKT expression did’t have signifi-
cant changes between each three group (P > 0.05), p-AKT
was decreased after Maspin overexpression (P < 0.05). And
mTOR, a substrate of the PI3K/AKT signaling pathway,
was downregulated in Maspin group (P < 0.05). We also
found apoptosis related molecules Caspase3 was increased
and Bcl-2 decreased in Maspin group (P < 0.05) (Fig. 5).
Maspin expression in the MIBC patient samples
To assess Maspin expression in the samples of MIBC
patient receiving cisplatin based chemotherapy, Maspin
protein was detected in the nucleus and cytoplasm of
the MIBC specimens. There were 23 (37.1 %) cases of
Maspin (+) and 39 (62.9 %) cases of Maspin (−) in all
MIBC cases (Fig. 6a, b). We also saw the micro-vessels
invasion (Fig. 6c) in 41 (66.1 %) cases and lymph node
metastasis (Fig. 6d) in 34 (54.8 %) cases.
Maspin expression in correlation with the prognosis of
MIBC patients receiving cisplatin based neoadjavant
chemotherapy
To determine if Maspin was associated with the prognosis
of MIBC patient receiving cisplatin based neoadjuvant
chemotherapy, patients’ survival was analyzed with log-
rank test (Table 2) and Kaplan-Meier survival curves
(Fig. 7). In all 62 MIBC patients, the overall survival (OS)
rate among the patients with Maspin (−) expression level
was potentially significantly lower than that among the
patients with Maspin (+) expression (P = 0.0036). The
progression-free survival (PFS) rate among patients with
maspin (−) expression level was also potentially signifi-
cantly lower than that among the patients with Maspin
(+) expression (P = 0.0005). These results showed Maspin
(+) expression was correlated with good prognosis in
MIBC patients who underwent cisplatin based NACT.
Discussion
Maspin is a 42-kDa protein associated with various
tumor related processes such as the inhibition of cell mi-
gration, cell invasion, angiogenesis, as well as improve-
ment in cell adhesion and the induction of programmed
cell death, thus classifying it as a tumor suppressor
[15–17]. Emerging evidence shows that Maspin expres-
sion was preserved in superficial bladder cancers and
its expression associated with good prognosis. Kramer
[18] investigated specimens from 162 non-muscle inva-
sive bladder cancer patients treated by transurethral re-
section. They showed positive Maspin expression rate
was 75.9 % and had a longer PFS compared with nega-
tive expression (46 vs 18 months, respectively). And
Acikalin, Blandamura also concluded similar results on
Maspin expression and superficial bladder cancer [19, 20].
In our study, there were 23 (37.1 %) cases of Maspin (+)
in 62 MIBC cases. The OS and PFS rate among patients
with Maspin (−) were significantly lower than these
among patients with Maspin (+) expression (P = 0.0036
and 0.0005, respectively). This expression rate was lower
than the reported results in superficial bladder cancer
Fig. 2 Expression levels of Maspin post-transfection in bladder cancer T24 and 5637 cells. The mRNA and protein levels of Maspin in bladder cancer
T24 and 5637 cells transfected with pcDNA3.1-Maspin or negative control (pcDNA3.1-con) were detected by RT-PCR and western blot. a and b were
showed mRNA level of T24 and 5637 cells, respectively. And c and d were showed protein expression level. *P < 0.05. Three independent experiments
were performed (n = 3)
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while it correlated with the Beecken’s study [10], who
showed Maspin was significantly diminished in MIBC and
patients with high Maspin expression had relatively good
prognosis.
Aa a tumor suppressor, Maspin has been found to in-
crease cell apoptosis induced by chemo-regents in several
types of cancers. Jiang et al. found Maspin transfected
MDA-MB-435 breast carcinoma cells displayed in-
creased sensitivity to staurosporine induced apoptosis
[21]. Ben et al. testified Maspin could mediate E2F1-
induced apoptosis of U2OS and SAOS2 osteosarcoma
cells to doxorubicin and cisplatin [22]. Additional support-
ing evidence using prostate cancer cells had also reported
that Maspin induced apoptosis sensitivity to chemical re-
agents [23], as well as increased the rate of apoptosis
related to inhibition of proteosomal pathways [24].
In addition to surgical treatment, chemotherapy is an
important strategy for the therapy of MIBC. Cisplatin
Fig. 3 Effects of Maspin on proliferation and sensitivity to cisplatin of T24 and 5637 cells. a was showed the cell viability with different cisplatin
measured by MTT assay. b was showed the IC50 value in each group. Cloning efficiency was calculated after cultured for 2 weeks. c and d showed the
representative results of colony formation assay. Overexpression of Maspin dramatically decreased the cell viability, IC50 value and clone-formation,
respectively. *P < 0.05. Three independent experiments were performed (n = 3)
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based chemotherapy is widely used in bladder cancer
treatment [25]. However, a significant proportion of pa-
tients develop disease progression after an initial re-
sponse to chemotherapy. The drug resistance affect the
therapeutic efficacy of bladder cancer treatment [26].
Recently, several molecules and reagents had been found
to enhance chemosensitivity in bladder cancer, such as
miR-101, TFAP2a, LRIG1, 5-Azacytidine, LY294002, et
al. [27–32]. But the crosstalk between Maspin and cis-
platin based chemosensitiviy is rare till now. In the
present study, our results showed that Maspin overex-
pression increased the cell apoptosis and enhanced che-
mosensitivity of both T24 and 5637 cells to cisplatin,
with the IC50 value decreasing from 23.32 ± 4.30 mg/l
to 15.30 ± 2.10 mg/l and from 4.91 ± 0.42 mg/l to 2.14 ±
0.21 mg/l, respectively. Further more, in MIBC patients
treating with NACT plus RC-PLND, Maspin expression
was correlated with the prognosis, showing the OS and
PFS rates were much longer in Maspin(+) group.
Bcl-2, a 26-kDa integral, is a powerful endogenous
anti-apoptosis protein that in response to a variety of
cell death signals [33]. Research showed it negatively
regulated the activation of Caspase-3, the key execu-
tioner of apoptosis, which functions as an effector of
mammalian cell death pathways. Downexpression of
Bcl-2 promote Caspase activities and apoptosis [34]. The
Fig. 4 Effects of Maspin on cisplatin-induced cell apoptosis in T24 and 5637 cells. Apoptotic cells were detected by Annexin V-FITC and PI double
staining and analyzed by flow cytometry. a and b were showed maspin overexpression enhanced cell apoptosis induced by cisplatin in T24 and
5637 cells, respectively. *P < 0.05. Three independent experiments were performed (n = 3)
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Fig. 5 Western blotting analysis of proteins related to apoptosis in T24 and 5637 cells. a was showed AKT, p-AKT, PI3K, mTOR, Caspase3 and Bcl-2
expression in T24 and 5637 cells measured by immunoblotting. And β-actin was used as an internal control. b and c were showed the relative
protein levels normalized to β-actin in T24 and 5637 cells, including Con, NC and Maspin group, respectively. AKT expression did’t have significant
changes between each three group (P > 0.05). p-AKT, PI3K, mTOR, and Bcl-2 expression were significantly decreased, whereas Caspase3 was
greatly increased in the Maspin group. *P < 0.05. Three independent experiments were performed (n = 3)
Fig. 6 Immunohistochemistry of bladder cancer tissue with Maspin antibody. a showed negative(−) stain of Maspin in MIBC sample. b showed
positive(+) stain of Maspin in MIBC sample. c showed bladder cancer cells invaded into micro-vessels. d showed the lymph node metastasis of
bladder cancer cells. (a, b, c and d, magnification, ×400)
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present study results show upregulation of the Maspin
expression in T24 and 5637 cells, resulting in a decrease
in the Bcl-2 level, with a concurrent increase in the
Caspase-3 activation. Recent evidence indicates that
AKT is frequently activated in many types of human
cancer, and activated PI3K/AKT/mTOR signaling pathway
is a significant contributor to tumor progression and poor
prognosis, including bladder cancer [35]. Moreover, AKT
overexpression is often associated with resistance to cis-
platin chemotherapy, such as in ovarian and lung cancer,
et al. [36, 37]. Sun et al. testified MK2206, a highly potent
and selective allosteric AKT inhibitor, could promote the
cisplatin-induced cytotoxicity and apoptosis in urothelial
cancer cell lines through inhibiting the Akt pathway [38].
Wu and his colleagues found LY294002, a PI3K inhibitor,
could suppress proliferation and sensitize doxorubicin
chemotherapy in bladder cancer EJ cells. Our results
showed that compared with control group, though AKT
expression did’t have significant changes, p-AKT, PI3K
and mTOR expression were significantly decreased in
Maspin group. So, the above results suggest upregulat-
ing Maspin expression could enhance cisplatin chemosen-
sitivity and was induced by cell apoptosis through PI3K/
AKT/mTOR signaling pathway in T24 and 5637 cells.
As concluded by Berardi, there are three strategies
to re-activate or increase Maspin expression [8]. The
first one is designing transcription factors, to hit the
system that inhibits the expression of maspin, such as
artificial transcription factors (ATFs) and chromatin
remodeling drugs [39]. In our previous study, we found a
DNA methyltransferase inhibitor, 5-aza-2′-deoxycytidine
(5-Aza-CdR), could reactivate Maspin expression and in-
hibit the proliferation, migration, and invasion of T24
cells, which may serve as a potential strategy for the treat-
ment of bladder cancer [40]. The second one is identifying
natural substances that can determine the activation and
the expression of Maspin, such as curcumin, a hydropho-
bic polyphenol derived from turmeric [41]. And Last but
not least, gene therapy capable of up-regulating the
Maspin in cancer cell, such as Maspin DNA-liposome
therapy and adeno-associated virus (AAV, serotype 2)
vector encoding Maspin [42, 43].
Conclusions
In conclusion, Maspin could enhance cisplatin chemo-
sensitivity induced by cell apoptosis in MIBC T24 and
5637 cell lines. The probable mechanism was associated
with PI3K/AKT/mTOR signaling pathway. Its expression
correlated with prognosis of MIBC patients who received
cisplatin-based NACT. This study provides new insight
into Maspin’s role in MIBC and shows its promise as a po-
tential molecular target for bladder cancer.
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Table 2 Log-rank test of Maspin expression with MIBC survival
time
Log rank (Mantel-Cox) χ2 95 % CI P value
Maspin and OS 8.49 1.521–8.515 0.0036
Maspin and PFS 12.17 1.725–6.980 0.0005
OS overall survival, PFS progression-free survival, CI confidence interval. P < 0.05
was considered statistically significant
Fig. 7 The relationship between Maspin staining and survival rate in
MIBC patients receiving NACT plus RC-PLND. a and b showed Kaplan-
Meier survival curves of the OS and PFS in the 62 patients, respectively.
The results indicated Maspin expression was related to OS and PFS
(P = 0.0036 and 0.0005, respectively)
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